Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.

SRR9879266

· cohortMD2

4d6e0154-6687-50ab-bef5-bd0eeda54666

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
cancer_type_detailed
subtype
cohortMD2
subtype
cohortMD2

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • MITOTIC_SPINDLE+0.440
  • ALLOGRAFT_REJECTION+0.350
  • INTERFERON_GAMMA_RESPONSE+0.350
  • INTERFERON_ALPHA_RESPONSE+0.340
  • PROTEIN_SECRETION+0.300
  • G2M_CHECKPOINT+0.260
  • UV_RESPONSE_DN+0.250
  • E2F_TARGETS+0.200
  • FATTY_ACID_METABOLISM+0.160
  • IL6_JAK_STAT3_SIGNALING+0.160

Top 10 suppressed

  • ANGIOGENESIS-0.430
  • TNFA_SIGNALING_VIA_NFKB-0.370
  • HYPOXIA-0.350
  • ESTROGEN_RESPONSE_EARLY-0.320
  • P53_PATHWAY-0.320
  • COAGULATION-0.300
  • ESTROGEN_RESPONSE_LATE-0.300
  • PANCREAS_BETA_CELLS-0.300
  • WNT_BETA_CATENIN_SIGNALING-0.300
  • UV_RESPONSE_UP-0.270

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

9 twins match this tumor's tissue · 1 come from a different tissue of origin

#SampleCancer typeSubtypecos similarity
16b375859-116e-4a5e-b5b4-994a56cc9a75
melanoma-umap@29
0.859
2e0b0b87d-1125-4834-8133-5d719f1fd255
melanoma-umap@29
0.798
3MNG724
mng-umap@100
0.797
4MDT-AP-3309
medullo-epn-umap@date-based
MedMedulloblastoma0.797
5MNG833
mng-umap@100
0.789
6GSM6454730
breast-umap@18
D0.777
7aMVAC.P_006_TURBT_S224
bladder-landscape@3
0.775
8MNG1220
mng-umap@100
0.772
9b652254e-228b-40d4-be79-536ad87dad69
melanoma-umap@29
0.768
10MNG1021
mng-umap@100
0.751

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 19 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
MITOTIC_SPINDLE0.440Inavolisib— uncovered
ALLOGRAFT_REJECTION0.350Idelalisib— uncovered
INTERFERON_GAMMA_RESPONSE0.350Idelalisib— uncovered
INTERFERON_ALPHA_RESPONSE0.340Inavolisib— uncovered
PROTEIN_SECRETION0.300Remibrutinib— uncovered
G2M_CHECKPOINT0.260Inavolisib— uncovered
UV_RESPONSE_DN0.250Inavolisib— uncovered
E2F_TARGETS0.200Inavolisib— uncovered
FATTY_ACID_METABOLISM0.160Inavolisib— uncovered
IL6_JAK_STAT3_SIGNALING0.160Inavolisib— uncovered
UNFOLDED_PROTEIN_RESPONSE0.160Idelalisib— uncovered
COMPLEMENT0.090Inavolisib— uncovered
BILE_ACID_METABOLISM0.070Inavolisib— uncovered
ANDROGEN_RESPONSE0.050Inavolisib— uncovered
HEME_METABOLISM0.050Temsirolimus— uncovered
PEROXISOME0.040Idelalisib— uncovered
SPERMATOGENESIS0.040Inavolisib— uncovered
PI3K_AKT_MTOR_SIGNALING0.020Inavolisib— uncovered
DNA_REPAIR0.010Idelalisib— uncovered